Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Replimune Group, Inc. (REPL) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update",
"Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB099280 in Patients with Cutaneous Squamous Cell Carcinoma"
05/18/2023 8-K Quarterly results
Docs: "Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update"
02/09/2023 8-K Quarterly results
Docs: "Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update"
08/04/2022 8-K Quarterly results
05/19/2022 8-K Quarterly results
02/03/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update"
08/06/2021 8-K Quarterly results
Docs: "Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update"
05/20/2021 8-K Quarterly results
02/04/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update"
08/07/2020 8-K Quarterly results
08/07/2020 8-K Quarterly results
06/03/2020 8-K Quarterly results
Docs: "Replimune Reports Fiscal Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update Woburn, MA, June 3, 2020 – Replimune Group, Inc. , a biotechnology company developing a series of oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced financial results for the fiscal fourth quarter and year ended March 31, 2020 and provided a business update. “I am very pleased with our continued progress developing our pipeline of oncolytic immuno-gene therapies. Today we released additional data with RP1 in our lead indications of cutaneous squamous cell carcinoma and anti-PD1 refractory cutaneous melanoma that we believe point to a high probability of success in our registration-directed clinical trial in CSCC and our potentially registration..."
11/12/2019 8-K Quarterly results
08/14/2019 8-K Quarterly results
06/28/2019 8-K Quarterly results
02/14/2019 8-K Quarterly results
11/14/2018 8-K Quarterly results
Docs: "Replimune Reports Financial Results for the Second Fiscal Quarter, Ended September 30, and Provides Development and Corporate Update"
08/30/2018 8-K Quarterly results
Docs: "Replimune Reports Financial Results for the First Fiscal Quarter, Ended June 30, and Provides Development and Corporate Update"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy